Price3.96%   -2.58
Oct-06-22 08:45AM The Zacks Analyst Blog Highlights CRISPR Therapeutics, Editas Medicine, Sarepta Therapeutics and Beam TherapeuticsZacks Investment Research
Oct-05-22 09:18AM 4 Biotechs to Watch Amid Rising Prominence of Gene TherapiesZacks Investment Research
08:15AM Where to Invest $500 Right NowThe Motley Fool
Oct-05-22 08:05AM CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingGlobeNewswire Inc.
Oct-04-22 06:40AM 1 Growth Stock That'll Beat Amazon and 1 That Probably Won't (for Now)The Motley Fool
Oct-03-22 09:16AM bluebird's (BLUE) Gene Therapy Approvals to Drive the Top LineZacks Investment Research
Oct-02-22 10:00AM 2 Top Biotech Stocks to Buy for the Long HaulThe Motley Fool
Sep-29-22 05:52AM 3 Stocks to Buy if You're Afraid to Buy StocksThe Motley Fool
05:20AM 3 Reasons Why Cathie Wood Won't Touch This Warren Buffett StockThe Motley Fool
Sep-28-22 01:17AM Vertex (VRTX), CRISPR to Seek FDA Nod for Hemoglobinopathy TherapyZacks Investment Research
06:20AM The 2 Best Stocks to Invest $5,000 in Right NowThe Motley Fool
Sep-27-22 05:52AM Why Vertex Pharmaceuticals Stock Triumphed On TuesdayThe Motley Fool
Sep-24-22 05:52AM Recession Fears Increasing: Here's the Best Stock to Buy Right NowThe Motley Fool
Sep-19-22 05:35AM "The Era of the Gene-Edited Human Is Here"The Motley Fool
10:15AM 2 Risky Cathie Wood Growth Stocks to Buy and Hold for 5 YearsThe Motley Fool
Sep-17-22 10:07AM 2 Biotech Stocks That Could Make You RicherThe Motley Fool
Sep-15-22 07:16AM If You've Got $5,000, Buying These 5 Top Stocks Right Now Would Be a Genius MoveThe Motley Fool
Sep-07-22 11:30AM CRISPR Therapeutics AG (CRSP) Down 16.5% Since Last Earnings Report: Can It Rebound?Zacks Investment Research
Sep-06-22 10:34AM CRISPR Therapeutics' (CRSP) Pipeline Development Fuels GrowthZacks Investment Research
10:30AM The Best Biotech Stock to Own in SeptemberThe Motley Fool
Aug-29-22 10:23AM 3 Biotech Stocks You Can Buy and Hold for the Next DecadeThe Motley Fool
Aug-27-22 06:08AM 3 Growth Stocks Poised to SkyrocketThe Motley Fool
Aug-22-22 09:04AM Vertex (VRTX) Stock Up 36% This Year So Far: What Lies Ahead?Zacks Investment Research
Aug-20-22 06:10AM 3 Monster Stocks in the Making to Buy Right NowThe Motley Fool
Aug-17-22 06:33AM Why This Analyst Sees A 51% Return On This Cathie Wood-Favored Biotech StockBenzinga
Aug-09-22 03:26AM Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In USBenzinga
10:13AM Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022Benzinga
Aug-09-22 09:05AM CRISPR Therapeutics (CRSP) Q2 Earnings & Sales Miss EstimatesZacks Investment Research
07:30AM Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This StockBenzinga
Aug-09-22 06:44AM NVIDIA To $240? Here Are 5 Other Price Target Changes For TuesdayBenzinga
Aug-08-22 09:15AM CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research
08:00AM CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewswire Inc.
Aug-06-22 09:45AM UC Berkeley's Chief Innovation Officer Talks Interest Rates, Crypto, and MoreThe Motley Fool
01:07AM Vertex Q2: Betting Big On Quality Over QuantitySeeking Alpha
Aug-05-22 09:33AM Vertex (VRTX) Beats on Q2 Earnings, Ups 2022 Sales GuidanceZacks Investment Research
12:32PM Cathie Wood Sheds $5M In CRISPR Therapeutics, Scoops Up These Biotech Stocks InsteadBenzinga
Jun-03-22 10:00AM 2 Green Flags for Vertex Pharmaceuticals' FutureThe Motley Fool
May-22-22 06:00AM Have $2,000? 2 Market Crash-Ready Stocks to BuyThe Motley Fool
May-18-22 09:06AM Vertex (VRTX) Outperforms Industry This Year So Far: Here's WhyZacks Investment Research
May-17-22 12:03PM Analyst Ratings for CRISPR TherapeuticsBenzinga
May-16-22 02:23AM CRISPR (CRSP) Focuses on Pipeline Amid Lack of Marketed DrugsZacks Investment Research
May-14-22 06:30AM Here's the No. 1 Reason to Buy Vertex Pharmaceuticals NowThe Motley Fool
May-13-22 11:52AM Why Editas Medicine's Shares Fell 28.9% This WeekThe Motley Fool
11:45AM 2 Stocks With 75% to 183% Upside, According to Wall StreetThe Motley Fool
May-13-22 10:32AM These 5-Stock Samplers Have Gotten Whacked. And That's OKThe Motley Fool
May-12-22 04:19AM Why Cathie Wood's Flagship ETF Slumped This WeekThe Motley Fool
10:33AM CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid CongressGlobeNewswire Inc.
May-10-22 02:23AM Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial DataBenzinga
10:30AM CRISPR Therapeutics (CRSP) Q1 Earnings & Sales Miss EstimatesZacks Investment Research
May-09-22 05:15AM CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient. The company is also developing CTX101, a donor-derived gene-edited allogeneic CAR-T therapy targeting CD19-positive malignancies. In addition, it is developing earlier stage allogeneic CAR-T programs targeting B-Cell maturation antigen and CD70; hemoglobinopathies to treat other diseases, including Hurler Syndrome and severe combined immunodeficiency disease; programs that are in preclinical development for indications, including glycogen storage disease Ia and hemophilia; and programs targeting diseases of organ systems outside the liver, such as Duchenne muscular dystrophy and cystic fibrosis. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated Vertex Pharmaceuticals (Europe) Limited to develop, manufacture, commercialize, sell, and use therapeutics. The company also has research collaboration agreements with Neon Therapeutics for developing neoantigen-based therapeutic vaccines and T cell therapies; Massachusetts General Hospital Cancer Center to develop T cell therapies for cancer; and with the ViaCyte, Inc. for designing allogeneic cell therapies derived from gene edited human stem cells for use in the treatment of diabetes type 1, diabetes type 2, and insulin dependent diabetes. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.
Cap:    |  Volume (24h):